EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Semaglutide Modulates Visceral Adipose Tissue Lipid Metabolism in Type 2 Diabetic Mice: A Lipidomics Study

Xinlei Chen, Bingrou Tu, Zhaoyuan Li, Ping Gao, Yi Xu, Yue Yao

Frontiers in Bioscience-Landmark · 2026-06-22 · 31 (6)

DOI: 10.31083/fbl49873 ↗

At a glance

Journal article in Frontiers in Bioscience-Landmark, published online on 2026-06-22. Written by Xinlei Chen and 5 co-authors. Institution: Department of Endocrinology and Metabolism, Second Affiliated Hospital of Harbin Medical University, 150000 Harbin, Heilongjiang, China. Major MEDLINE topics: Lipid Metabolism, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Intra-Abdominal Fat. 64 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Natural Science Foundation of China.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background:Type 2 diabetes mellitus (T2DM) is a major public health challenge. This study aimed to explore the molecular mechanisms underlying the effects of semaglutide on lipid metabolism in visceral white adipose tissue in a mouse model of T2DM.Methods:Male C57BL/6J mice were given a normal diet, a high-fat diet with streptozotocin, or a high-fat diet with semaglutide. Blood samples, liver tissue, and adipose tissue were collected for analysis. Serum adipokines, inflammatory cytokines, liver function, and lipid profiles were assessed. White adipose tissue and liver sections were processed for hematoxylin and eosin (H&E) staining or immunohistochemistry (IHC) staining for the macrophage marker F4/80. High-throughput targeted lipidomic analysis of epididymal white adipose tissue from these animals was performed using liquid chromatography-tandem mass spectrometry to characterize changes in lipid composition and function. Furthermore, the expression of genes related to adipokines, inflammation, and lipid metabolism in epididymal adipose tissue was determined by reverse transcription-quantitative PCR (RT-qPCR).Results:Semaglutide significantly improved systemic metabolism in mice with T2DM, as demonstrated by reductions in body weight, blood glucose, serum lipid levels, and insulin resistance indices homeostasis model assessment of insulin resistance (HOMA-IR) and adipose tissue insulin resistance index (Adipo-IR). Serum Leptin, interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-α) levels were downregulated, while Adiponectin levels were elevated. Histological analysis revealed that semaglutide effectively reduced adipocyte size, suppressed macrophage infiltration in adipose tissue, and decreased liver lipid accumulation. Targeted lipidomic profiling identified 24 lipid subclasses, of which 50 lipid molecules were significantly changed after semaglutide treatment. Enrichment analysis identified 15 metabolic pathways, with glycerophospholipid metabolism being the most prominently affected. RT-qPCR results confirmed that semaglutide altered the expression of key genes involved in glycerolipid, glycerophospholipid, fatty acid, and cholesterol metabolism.Conclusions:These results shed light on the comprehensive remodeling of semaglutide in improving lipid metabolism in epididymal white adipose tissue mice with T2DM.

Subjects

MeSH terms (MEDLINE)

Lipid MetabolismDiabetes Mellitus, Type 2Glucagon-Like PeptidesIntra-Abdominal FatDiabetes Mellitus, ExperimentalAnimalsSemaglutideMaleMiceMice, Inbred C57BLLipidomicsDiet, High-FatLiverInsulin ResistanceAdipose Tissue, White

Author keywords

adipose tissue, whitediabetes mellitus, type 2lipid metabolismsemaglutide

Substances

SemaglutideGlucagon-Like Peptides

Authors and institutions

  • Department of Endocrinology and Metabolism, Second Affiliated Hospital of Harbin Medical University, 150000 Harbin, Heilongjiang, China.
  • Department of Pathology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
  • Department of Hepatopancreatobiliary Surgery, Second Affiliated Hospital of Harbin Medical University, 150000 Harbin, Heilongjiang, China.

Funding

  • National Natural Science Foundation of China

Cite

APA

Chen, X., Tu, B., Li, Z., Gao, P., Xu, Y., & Yao, Y. (2026). Semaglutide Modulates Visceral Adipose Tissue Lipid Metabolism in Type 2 Diabetic Mice: A Lipidomics Study. Frontiers in Bioscience-Landmark, 31(6). https://doi.org/10.31083/fbl49873

Vancouver

Chen X, Tu B, Li Z, Gao P, Xu Y, Yao Y. Semaglutide Modulates Visceral Adipose Tissue Lipid Metabolism in Type 2 Diabetic Mice: A Lipidomics Study. Frontiers in Bioscience-Landmark. 2026;31(6). doi:10.31083/fbl49873

BibTeX
@article{Chen2026,
  author = {Chen, Xinlei and Tu, Bingrou and Li, Zhaoyuan and Gao, Ping and Xu, Yi and Yao, Yue},
  title = {Semaglutide Modulates Visceral Adipose Tissue Lipid Metabolism in Type 2 Diabetic Mice: A Lipidomics Study},
  journal = {Frontiers in Bioscience-Landmark},
  year = {2026},
  volume = {31},
  number = {6},
  doi = {10.31083/fbl49873}
}
Start for free →